ALK was first described in 1994 as the NPM-ALK fusion protein that is expressed in the majority of anaplastic large-cell lymphomas (ALCL), approximately 55% of adult patients and more than 90% of pediatric patients [3]. Here, ALK is linked to anaplastic large cell lymphoma.